Page last updated: 2024-08-23

pirfenidone and Pneumonia, Viral

pirfenidone has been researched along with Pneumonia, Viral in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	3 (100.00)	2.80

Authors

Authors	Studies
Chang, WT; Liu, PY; Ragazzi, E; Wu, SN	1
Ferrara, F; Granata, G; La Porta, R; Pelliccia, C; Vitiello, A	1
Aguirre-Plans, J; Artigas, L; Barbera, J; Coma, M; de la Haba-Rodriguez, J; Farrés, J; Fernandez-Fuentes, N; Mas, JM; Matos-Filipe, P; Morales, R; Oliva, B; Olvera, A; Valls, R	1

Reviews

1 review(s) available for pirfenidone and Pneumonia, Viral

Article	Year
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? European journal of clinical pharmacology, 2020, Volume: 76, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Inflammation; Interleukin-1; Interleukin-6; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Pyridones; SARS-CoV-2	2020

Article

Year

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?

European journal of clinical pharmacology, 2020, Volume: 76, Issue:11

Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Inflammation; Interleukin-1; Interleukin-6; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Pyridones; SARS-CoV-2

2020

Other Studies

2 other study(ies) available for pirfenidone and Pneumonia, Viral

Article	Year
Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target. European journal of pharmacology, 2020, Sep-05, Volume: 882 Topics: Animals; Betacoronavirus; Cations; Cell Line, Tumor; Cell Membrane; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Ion Channels; Ion Transport; Membrane Potentials; Pandemics; Pneumonia, Viral; Potassium; Pyridones; Rats; SARS-CoV-2; Sodium	2020
In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PloS one, 2020, Volume: 15, Issue:10 Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Pharmaceutical; Drug Repositioning; Furin; Humans; Melatonin; Pandemics; Pneumonia, Viral; Pyridones	2020

Article

Year

Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.

European journal of pharmacology, 2020, Sep-05, Volume: 882

Topics: Animals; Betacoronavirus; Cations; Cell Line, Tumor; Cell Membrane; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Ion Channels; Ion Transport; Membrane Potentials; Pandemics; Pneumonia, Viral; Potassium; Pyridones; Rats; SARS-CoV-2; Sodium

2020

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.

PloS one, 2020, Volume: 15, Issue:10

Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Pharmaceutical; Drug Repositioning; Furin; Humans; Melatonin; Pandemics; Pneumonia, Viral; Pyridones

2020